Litigation Details for AbbVie Inc. v. Gilead Sciences Inc. (D. Del. 2014)

AbbVie Inc. v. Gilead Sciences Inc. (D. Del. 2014)

Docket		Date Filed	2014-02-18
Court	District Court, D. Delaware	Date Terminated	2016-08-24
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Plaintiff	Referred To
Patents	8,466,159; 8,492,386
Link to Docket	External link to docket

Details for AbbVie Inc. v. Gilead Sciences Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-02-18				External link to document

AbbVie Inc. v. Gilead Sciences Inc. Litigation Summary, Case No. 1:14-cv-00209

Last updated: August 18, 2026

AbbVie Inc. v. Gilead Sciences Inc., No. 1:14-cv-00209, was a District of Delaware patent dispute involving AbbVie’s hepatitis C virus, or HCV, patent portfolio and Gilead’s commercially important HCV products. AbbVie filed the action in 2014 as Gilead’s Sovaldi franchise rapidly expanded. The case ended through a negotiated dismissal rather than a publicly reported merits judgment establishing infringement, patent validity, or a royalty obligation. Public docket materials do not disclose the settlement’s commercial terms. (U.S. District Court for the District of Delaware, 2014-2017)

What was AbbVie v. Gilead about?

AbbVie alleged that Gilead’s HCV products infringed patent rights relating to HCV antiviral compounds and treatment technology. The dispute arose during the launch period for Sovaldi, Harvoni, and AbbVie’s competing Viekira Pak regimen.

Gilead’s HCV portfolio included:

• Sovaldi, or sofosbuvir
• Harvoni, a fixed-dose combination of ledipasvir and sofosbuvir
• Other later HCV combinations containing sofosbuvir or related antiviral agents

AbbVie’s competing portfolio included:

• Viekira Pak
• Technivie
• Viekirax in certain non-U.S. markets
• Patent rights covering HCV direct-acting antiviral compounds, combinations, and treatment methods

The case was commercially significant because Sovaldi and Harvoni became major U.S. pharmaceutical products. A successful injunction or royalty award could have affected Gilead’s access to the HCV market during the period of peak treatment demand.

What was the procedural history of case 1:14-cv-00209?

Event	Date	Significance
AbbVie filed the complaint	2014	Initiated the HCV patent dispute in the District of Delaware
Gilead responded and contested AbbVie’s claims	2014 onward	The case proceeded as an infringement and patent-validity dispute
Discovery and claim-construction proceedings	2014-2016 period	The parties litigated the scope and enforceability of the asserted rights
Settlement and stipulated dismissal	Before final merits judgment	Terminated the action without a reported public trial verdict
Case closed	Docket-dependent closure date	No public injunction or damages judgment resulted from the action

The docket is associated with the District of Delaware and was assigned to Judge Richard G. Andrews. The public record does not establish a final judicial determination that Gilead infringed an enforceable AbbVie patent.

What patents were at issue?

The litigation concerned AbbVie HCV patent rights directed to antiviral compounds, pharmaceutical compositions, and treatment approaches. The case should not be treated as a final judicial determination on the validity of every AbbVie HCV patent family.

A key analytical distinction is necessary:

1. The case docket identifies the litigated patent dispute.
2. AbbVie and Gilead held broader HCV patent portfolios beyond the patents asserted in this action.
3. Patent-family coverage, Orange Book listing, and expiration dates must be assessed patent by patent.
4. The settlement did not create a public precedent confirming the validity or infringement scope of the asserted claims.

The public case record does not provide a merits opinion that resolves the full scope of the asserted claims. As a result, the litigation is more useful for assessing commercial settlement risk than for determining claim construction or validity precedent.

Did AbbVie win or did Gilead win?

Neither company received a publicly reported merits victory in the case.

The action ended through settlement and dismissal. That disposition means:

• AbbVie did not obtain a public damages award.
• AbbVie did not obtain a publicly reported permanent injunction against Sovaldi or Harvoni.
• Gilead did not obtain a final judgment invalidating all asserted AbbVie patents.
• The court did not issue a binding infringement ruling defining the parties’ HCV patent rights.
• The parties’ commercial resolution was not fully disclosed in the public docket.

The appropriate classification is a negotiated termination, not a litigated win for either side.

What was the commercial importance of the litigation?

The lawsuit was filed during an unusually concentrated period of HCV product competition.

Gilead’s Sovaldi launched in the United States in December 2013. Harvoni received U.S. Food and Drug Administration approval in October 2014. AbbVie’s Viekira Pak received FDA approval in December 2014. These products competed in a market where treatment duration was short, cure rates were high, and payers faced substantial budget exposure. (FDA, 2013, 2014a, 2014b)

Gilead’s exposure

Gilead faced several forms of risk:

• A potential royalty on sales of accused products
• Restrictions on future product launches
• Additional patent litigation costs
• Delay in commercial expansion of Harvoni
• Uncertainty affecting licensing and acquisition strategy
• Potential impact on the value of its HCV franchise

AbbVie’s exposure

AbbVie also faced material risk:

• A finding of noninfringement could weaken its negotiating position
• Invalidity findings could reduce the value of its HCV patent estate
• A failed injunction strategy could leave Gilead’s products fully available
• Litigation costs could rise while Gilead’s market share expanded
• Viekira Pak could lose commercial relevance as treatment guidelines shifted toward simpler regimens

The settlement reduced litigation uncertainty for both parties while preserving access to the rapidly expanding HCV market.

Was there a Paragraph IV challenge?

The public record for this civil action should not be confused with an abbreviated new drug application, or ANDA, Paragraph IV case.

There is no basis to characterize AbbVie v. Gilead as a conventional generic-drug Paragraph IV action. Gilead was an innovator competitor, not an ANDA applicant challenging an Orange Book-listed patent to obtain approval for a generic version of AbbVie’s product.

The distinction matters:

Issue	AbbVie v. Gilead
Defendant	Innovator pharmaceutical company
Product dispute	Competing branded HCV products
ANDA Paragraph IV filing	Not the principal procedural basis
Orange Book patent certification	Not the central issue
Typical 30-month stay	Not the defining feature
Settlement type	Brand-versus-brand patent settlement

What was the FDA and Orange Book status?

Sovaldi, Harvoni, and Viekira Pak were approved new drug applications, or NDAs. They were not biosimilar products and were not conventional generic products.

Relevant FDA milestones included:

Product	Active ingredients	FDA milestone
Sovaldi	Sofosbuvir	Approved December 6, 2013
Harvoni	Ledipasvir/sofosbuvir	Approved October 10, 2014
Viekira Pak	Ombitasvir/paritaprevir/ritonavir plus dasabuvir	Approved December 19, 2014

(FDA, 2013, 2014a, 2014b)

The Orange Book status of any individual patent is separate from the existence of the civil case. A patent may be listed for a drug without being asserted in a particular action, and an asserted patent may not be the patent that ultimately controls generic entry.

The case also had no biosimilar dimension. Sofosbuvir and the other HCV active ingredients are small-molecule drugs. The relevant follow-on pathway is an ANDA or other small-molecule approval route, not the abbreviated biologics license application pathway.

Did the settlement establish a generic launch date?

No public record from the case establishes a generic launch date for Sovaldi, Harvoni, or Viekira Pak.

A brand settlement can contain:

• Patent licenses
• Royalty provisions
• Covenants not to sue
• Geographic restrictions
• Authorized generic terms
• Entry dates for future competitors
• Manufacturing or distribution rights

The public dismissal alone does not establish which of those provisions existed. It also does not establish that Gilead admitted infringement or that AbbVie conceded patent invalidity.

How strong was AbbVie’s patent estate after the case?

AbbVie’s HCV patent estate had commercial value, but the litigation outcome limited its value as a litigation precedent.

Strengths

• Coverage across antiviral compounds and treatment regimens
• Potential blocking rights over competing direct-acting antivirals
• Relevance to a large and rapidly expanding HCV market
• Negotiating leverage during the launch of Sovaldi and Harvoni
• Portfolio value beyond the individual patents asserted in the action

Limitations

• The case did not produce a published merits ruling validating the asserted claims.
• HCV products used multiple active ingredients and mechanisms, reducing the likelihood that one patent would control the entire treatment market.
• Rapid clinical development reduced the commercial life of some treatment-specific patents.
• Market demand shifted toward simpler, pan-genotypic regimens.
• The commercial value of Viekira Pak declined as newer therapies gained adoption.

The estate should therefore be assessed as a portfolio rather than through the result of this single docket.

What manufacturing and intellectual-property barriers were relevant?

The dispute involved more than active-ingredient claims. HCV product barriers could arise from:

• Compound patents
• Salt and crystalline-form patents
• Pharmaceutical composition patents
• Combination-product patents
• Treatment-method patents
• Dosing and duration claims
• Intermediate and manufacturing-process patents
• Formulation and tablet-coating claims
• Regulatory exclusivity

Gilead’s principal commercial defense was likely to depend on noninfringement and invalidity positions directed to the accused products and the particular claim limitations. AbbVie’s commercial leverage depended on whether its claims reached Gilead’s product architecture without relying on overly broad or vulnerable claim interpretations.

What litigation risks remained after dismissal?

The settlement ended this case but did not eliminate all HCV patent risk.

Potential residual risks included:

• Separate litigation involving different patent families
• Inter partes review or other validity challenges
• Patent disputes in foreign jurisdictions
• Contract or licensing disputes arising from the settlement
• Generic challenges to Orange Book-listed patents
• Manufacturing-process disputes
• Royalty or audit disputes, if the settlement included payments based on sales

The case also did not resolve the global patent position. U.S. dismissal has no automatic effect on corresponding European, Asian, Canadian, or other national rights.

How does this case compare with other Gilead HCV litigation?

AbbVie v. Gilead differs from several other Gilead HCV disputes.

Litigation type	Typical opposing party	Central issue	Public outcome profile
AbbVie v. Gilead	Branded innovator competitor	Competing HCV products and patent rights	Settlement and dismissal
Merck/Idenix v. Gilead	Branded company and acquired patent holder	Sofosbuvir-related patent rights	Separate merits litigation and damages disputes
Generic Paragraph IV cases	Generic manufacturers	Orange Book patents and ANDA approval	Possible 30-month stay, trial, settlement, or launch
University or research patent cases	Academic or research entities	Inventorship, priority, or foundational technology	Case-specific damages or validity rulings

The AbbVie action is best understood as a brand-versus-brand portfolio dispute rather than a generic-entry test case.

Key Takeaways

• AbbVie v. Gilead, No. 1:14-cv-00209, involved competing HCV patent portfolios and Gilead’s Sovaldi-era products.
• The action was filed during the launch cycle for Sovaldi, Harvoni, and Viekira Pak.
• The case ended through settlement and dismissal, not a publicly reported merits verdict.
• No public injunction, damages award, or comprehensive validity ruling resulted.
• The action was not a conventional ANDA Paragraph IV case.
• It had no biosimilar component because the products were small-molecule HCV drugs.
• Public materials do not disclose the settlement’s commercial terms or establish a generic entry date.
• The case reduced immediate litigation uncertainty but did not resolve the broader global HCV patent landscape.

FAQs

Did Gilead pay AbbVie to settle the case?

The public docket does not disclose the settlement’s financial terms. It does not establish whether the agreement included royalties, a lump-sum payment, cross-license rights, or other commercial consideration.

Did AbbVie’s lawsuit block Harvoni approval?

No public record indicates that the lawsuit blocked or delayed FDA approval of Harvoni. FDA approved Harvoni on October 10, 2014. (FDA, 2014a)

Did the case determine whether Sovaldi infringed AbbVie patents?

No. The case ended without a publicly reported final infringement judgment concerning Sovaldi.

Were AbbVie’s HCV patents invalidated?

No comprehensive invalidity judgment appears in the public disposition of this action. The dismissal did not invalidate AbbVie’s broader HCV patent portfolio.

Could a generic company rely on this settlement to launch an HCV product?

No. The settlement was between branded pharmaceutical companies and did not itself create a generally applicable generic launch right. Generic entry depended on the relevant product’s patents, regulatory exclusivity, ANDA certifications, and any separate settlement terms.

References

1. AbbVie Inc. v. Gilead Sciences, Inc., No. 1:14-cv-00209, U.S. District Court for the District of Delaware, docket materials, 2014-2017.

2. U.S. Food and Drug Administration. (2013, December 6). FDA approves first drug to treat hepatitis C genotype 2 and 3 infections. FDA.

3. U.S. Food and Drug Administration. (2014a, October 10). FDA approves first combination pill to treat hepatitis C. FDA.

4. U.S. Food and Drug Administration. (2014b, December 19). FDA approves Viekira Pak to treat hepatitis C. FDA.

5. Gilead Sciences, Inc. (2014-2017). Annual reports and securities filings. U.S. Securities and Exchange Commission.